TBCRC 019: An open label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel (nab-PAC) with or without the anti-death receptor 5 (DR5) monoclonal antibody tigatuzumab (TIG) in patients with metastatic triple negative breast cancer (TNBC) Meeting Abstract
| Authors: | Vakiavas, C.; Abramson, V. G.; Lin, N. U.; Liu, M. C.; Rugo, H. S.; Nanda, R.; Storniolo, A. M.; Traina, T. A.; Li, Y.; Patil, S.; Hayes, D. F.; Van Poznak, C. H.; Nangia, J. R.; Irvin, W. J.; Krontiras, H.; De Los Santos, J. F.; Haluska, P.; Wolff, A. C.; Forero-Torres, A. |
| Abstract Title: | TBCRC 019: An open label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel (nab-PAC) with or without the anti-death receptor 5 (DR5) monoclonal antibody tigatuzumab (TIG) in patients with metastatic triple negative breast cancer (TNBC) |
| Meeting Title: | 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 31 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2013 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2013-05-20 |
| Language: | English |
| ACCESSION: | WOS:000335419600292 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2013.31.15_suppl.1052 |
| Notes: | Meeting Abstract: 1052 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work